EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

EUROCARE 5 results where presented at the European Parliament on 5 December 2013. Some of the conclusions were:
• The number of adults survive at least 5 years after diagnosis has increased steadily over time in all regions of Europe from 1999 to 2007 , BUT STILL cancer survival varies widely between European countries.
• The countries with the lowest survival for most cancers (Bulgaria , Estonia, Latvia , Lithuania, Poland and Slovakia) are in Eastern Europe. Survival is lower than the European average.
• Nordic countries ( except Denmark ), the central European countries such as Austria, Belgium, France, Germany, Switzerland and the Netherlands, and in some southern European countries (Italy, Portugal and Spain) have a better survival for most part tumors.
• Large differences in survival are still present in the European Union.

 

For more information on EUROCARE 5, please click here or contact eurocare.secretariat@istitutotumori.mi.it.







Recent news

» EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myeloma

» EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myeloma

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.